Tom Stinchcombe

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

Jeffrey A. Bogart, Xiaofei F. Wang, Gregory A. Masters et al. · Journal of Clinical Oncology · 2021 · 37 citations

Medicine, Oncology, Radiation Oncology +15

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

Helen J. Ross, David Kozono, James J. Urbanic et al. · Journal of Clinical Oncology · 2021 · 36 citations

Medicine, Oncology, Pharmacology +17

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

Andrea B. Apolo, Jeffrey R. Infante, Omid Hamid et al. · Journal of Clinical Oncology · 2016 · 33 citations

Medicine, Oncology, Pharmacology +17

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

Tom Stinchcombe, Rolf A. Stahel, Lukas Bubendorf et al. · Journal of Clinical Oncology · 2017 · 31 citations

Medicine, Oncology, Immunotherapy +14

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Jacob Sands, Sumithra J. Mandrekar, Geoffrey R. Oxnard et al. · Journal of Clinical Oncology · 2020 · 31 citations

Medicine, Oncology, Chemotherapy +16